Loading…
Kamada Ltd. is projected to rise to $7.75 by 2027, a +9% move from its current price of $7.12. KMDA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $7.03 | $7.12 | $7.21 | +0.02% |
| Jul 13 | $6.99 | $7.12 | $7.26 | +0.05% |
| Jul 14 | $6.97 | $7.13 | $7.29 | +0.07% |
| Jul 15 | $6.94 | $7.13 | $7.31 | +0.10% |
| Jul 16 | $6.93 | $7.13 | $7.34 | +0.12% |
| Jul 17 | $6.91 | $7.13 | $7.36 | +0.15% |
| Jul 18 | $6.89 | $7.13 | $7.38 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.89 | $7.13 | $7.38 | +0.17% |
| Week 2 | $6.81 | $7.14 | $7.50 | +0.35% |
| Week 3 | $6.74 | $7.16 | $7.60 | +0.52% |
| Week 4 | $6.69 | $7.17 | $7.68 | +0.70% |
| Week 5 | $6.65 | $7.18 | $7.75 | +0.87% |
| Week 6 | $6.61 | $7.19 | $7.83 | +1.05% |
| Week 7 | $6.58 | $7.21 | $7.89 | +1.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.
The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Kamada Ltd. (KMDA) is a healthcare company focused on plasma-derived protein therapeutics. It operates within the healthcare sector and holds a market capitalization of $421.75M with a rank of 3201.
The current price is $7.31, reflecting the stock’s place in the market today. The near-term trading picture combines a current price near the SMA lines with a defined support at $7.13 and resistance at $7.98.
A major floor 6.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 10.4% above — a clean break opens room to run.
A major ceiling 29.1% above — clearing it would confirm fresh momentum.
Key KMDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KMDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.27 | Sell | $7.23 | Sell |
| MA 10 | $7.33 | Sell | $7.28 | Sell |
| MA 20 | $7.32 | Sell | $7.34 | Sell |
| MA 50 | $7.65 | Sell | $7.59 | Sell |
| MA 100 | $8.11 | Sell | $7.77 | Sell |
| MA 200 | $7.69 | Sell | $7.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.85 | Neutral |
| Stoch RSI (14) | 17.18 | Buy |
| CCI (20) | -113.51 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -0.14 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 34.28 | Neutral |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 7.14 | Sell |
| ADX (14) | 18.50 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is neutral overall, with RSI(14) at 40. The stock’s 50-day simple moving average stands at $7.71 and the 200-day SMA at $7.69, indicating a fairly balanced trend near the current level. A key near-term support sits at $7.13 and resistance at $7.98, framing a small trading band.
The 30-day price range spans from $6.68 to $8.00, underscoring modest volatility in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.03 | $7.12 | $9.19 | 0% | Neutral | |
| $6.35 | $7.75 | $9.89 | +9% | Neutral | |
| $6.54 | $8.14 | $10.67 | +14% | Neutral | |
| $7.92 | $10.01 | $13.40 | +41% | Bullish | |
| $8.68 | $11.11 | $15.14 | +56% | Bullish | |
| $9.37 | $12.15 | $16.82 | +71% | Bullish | |
| $9.86 | $12.93 | $18.15 | +82% | Bullish | |
| $9.40 | $12.45 | $17.71 | +75% | Bullish | |
| $10.30 | $13.77 | $19.82 | +93% | Bullish | |
| $11.60 | $15.67 | $22.80 | +120% | Bullish | |
| $15.07 | $21.23 | $32.38 | +198% | Bullish | |
| $30.32 | $45.79 | $74.87 | +543% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.03 | $7.12 | $8.44 | +0.00% |
| August 2026 | $6.24 | $7.30 | $8.73 | +2.55% |
| September 2026 | $6.19 | $7.28 | $8.78 | -0.26% |
| October 2026 | $6.07 | $7.17 | $8.70 | -1.59% |
| November 2026 | $6.17 | $7.31 | $8.92 | +1.97% |
| December 2026 | $6.30 | $7.50 | $9.19 | +2.57% |
Click any year to see its month-by-month KMDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The KMDA price prediction for 2026 points to an average of $7.12 (low $7.03, high $9.19) — a potential gain of 0% on today's $7.12. Price action looks broadly range-bound.
In 2027, KMDA is projected to trade between $6.35 and $9.89, averaging $7.75 — a potential gain of +9% from today's $7.12. That is up +9% on the projected 2026 average. A consolidation phase looks the most probable path here.
Kamada Ltd.'s 2028 outlook centres on $8.14, within a $6.54 to $10.67 range. That is up +5% on the projected 2027 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2029, KMDA could reach as high as $13.40, with a base case around $10.01 and support toward $7.92 — roughly +41% from $7.12. Buyers look set to stay in control over this stretch.
Expect KMDA to range from $8.68 to $15.14 through 2030. The $11.11 average target implies a +56% move from current prices. That is up +11% on the projected 2029 average. Momentum favours further upside here.
The KMDA price prediction for 2031 points to an average of $12.15 (low $9.37, high $16.82) — a potential gain of +71% on today's $7.12. Buyers look set to stay in control over this stretch.
In 2032, KMDA is projected to trade between $9.86 and $18.15, averaging $12.93 — a potential gain of +82% from today's $7.12. That is up +6% on the projected 2031 average. Momentum favours further upside here.
Kamada Ltd.'s 2033 outlook centres on $12.45, within a $9.40 to $17.71 range. That is -4% versus the projected 2032 average. That marks a +75% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, KMDA could reach as high as $19.82, with a base case around $13.77 and support toward $10.30 — roughly +93% from $7.12. Momentum favours further upside here.
Expect KMDA to range from $11.60 to $22.80 through 2035. The $15.67 average target implies a +120% move from current prices. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The KMDA price prediction for 2040 points to an average of $21.23 (low $15.07, high $32.38) — a potential gain of +198% on today's $7.12. Momentum favours further upside here.
In 2050, KMDA is projected to trade between $30.32 and $74.87, averaging $45.79 — a potential gain of +543% from today's $7.12. That is up +116% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in KMDA today (≈ 140.449438 KMDA) could be worth
$6,431.16
+$5,431.16 (+543%) by 2050 · US Dollar
Based on the average projected KMDA price of $45.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KMDAwould be worth at today's price.
$1,000 invested in KMDA on Jul 10, 2025 (≈ 124.688272 KMDA) would be worth
$887.78
-$112.22 (-11.2%) today · 0.89× · US Dollar
Based on a KMDA entry price of $8.02 vs. today's $7.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.5 | $949.33 | -5.1% |
| 1 month ago | $7.21 | $987.52 | -1.2% |
| 3 months ago | $8.49 | $838.63 | -16.1% |
| 6 months ago | $8.06 | $883.37 | -11.7% |
| 1 year ago | $8.02 | $887.78 | -11.2% |
| All time (5.0y) ago | $5.7 | $1,249.12 | +24.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KMDA forecast.
Our base-case forecast reaches $14.00 around 2035.
Implied market cap at $14.00: $807.72M
The year-by-year forecast shows a path from a 2026 average price of $7.31 toward progressively higher levels, ending with a 2050 average of $49.13 and a 572.1% ROI. The 2026 forecast carries an average of $7.31 with a 0% ROI and a neutral sentiment, while 2029–2032 turn bullish as averages rise to $10.47, $11.64 and $12.76 respectively, with ROIs of 43.3%, 59.2% and 74.6%. By 2034 the average reaches $14.61, and 2035 shows $16.65 with a 127.8% ROI.
The forecast then accelerates: 2040 average $22.69 with a 210.4% ROI, and by 2050 the average is $49.13 with a 572.1% ROI, all under bullish sentiment. These figures imply meaningful upside over the long term, though the outlook remains subject to uncertainty and is not guaranteed.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $11.64 with a range from $9.09 to $15.86 and an estimated ROI of 59.2%. The sentiment is BULLISH.
The forecast increases from a neutral stance in 2026 (avg $7.31) to bullish in later years, with 2029–2032 showing higher averages (e.g., 2029 avg $10.47; 2030 avg $11.64) and ROIs up to 59.2%. By 2040 the forecast shows an average of $22.69 and a 210.4% ROI, with a 2050 average of $49.13 and a 572.1% ROI, indicating substantial upside potential but not a guarantee.
Yes. The forecast for 2030 lists a maximum price of $15.86, and 2031 lists a maximum of $17.68, indicating that a price around or above $15 is within the projected range.
For 2040, the average price is forecast at $22.69, with a minimum of $16.11 and a maximum of $34.62, and a 210.4% ROI. The sentiment is BULLISH.
The numbers represent estimates and are not guaranteed. The current price is $7.31, and the forecast shows substantial upside in some years, but the outcomes are uncertain and can be affected by factors not captured in the numbers; historical volatility is indicated at about 30% annualized.
Kamada Ltd. Community Discussion
0Share your Kamada Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.